Skip to main content
SpringerLink
Log in

Pharmacologic Treatment of GERD

  • Chapter
  • First Online:
Gastroesophageal Reflux and the Lung

Part of the book series: Respiratory Medicine ((RM,volume 2))

  • 1332 Accesses

Abstract

Gastroesophageal reflux disease (GERD) is extremely common, affecting 7–10 % of the adult population in the United States on a daily basis [1]. GERD has been found to have a greater negative impact on quality of life for a patient than more severe chronic diseases, including hypertension, heart failure, and angina [2]. The clinical range of GERD has expanded from classic esophageal symptoms of heartburn and regurgitation to now include symptoms and disease outside the esophagus, namely, the entire aerodigestive tract. Treatment of the spectrum of reflux diseases, be it isolated to the esophagus or proximal disease of the oropharynx or lungs, shares a common pathophysiology, and therefore, similar treatment strategies can be implemented with only slight variations. There is a range of effective pharmacologic treatment options for patients with reflux disease: acute symptoms of classic reflux may simply require over-the-counter (OTC) acid-neutralizing medications, while other individuals with more persistent, recurring symptoms need a more directed, long-term strategy requiring systemic medications. The nature of the disease is one of chronicity. Thus, a majority of patients started on acid-suppressant medications will have symptoms that require long-term pharmacologic treatment. With the high prevalence of reflux disease, the spectrum of reflux manifestations, and the array of products available to treat reflux, the clinical and financial burden of treating reflux patients is high. This chapter focuses on the pharmacologic treatment for reflux disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Richter J. Surgery for reflux disease: reflections of a gastroenterologist. N Engl J Med. 1992;326(12):825–7.

    Article  PubMed  CAS  Google Scholar 

  2. Dimenas E. Quality of life in patients with upper gastrointestinal symptoms. Scand J Gastroenterol. 1993;28:681–7.

    Article  PubMed  CAS  Google Scholar 

  3. Tsuzuki T, Yamamoto K, et al. Proton pump inhibitor step-down therapy for GERD: a multicenter study in Japan. World J Gastroenterol. 2011;17(11):1480–7.

    Article  PubMed  CAS  Google Scholar 

  4. Marrewijk CJ, et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary care-based randomized controlled trial. Lancet. 2009;373:215–25.

    Article  PubMed  Google Scholar 

  5. Castell DO, Dalton CB, Becker D, et al. Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal strength antacid. Dig Dis Sci. 1992;37:589–93.

    Article  PubMed  CAS  Google Scholar 

  6. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983;28:559–63.

    Article  PubMed  CAS  Google Scholar 

  7. Tran T, Lowry A, El-Serag H. Meta-analysis: the efficacy of over-the-counter gastro-­oesophageal reflux disease drugs. Aliment Pharmacol Ther. 2007;25:143–53.

    PubMed  CAS  Google Scholar 

  8. Stanciu C, Bennett JR. Alginate/antacids in the reduction of gastroesophageal reflux. Lancet. 1974;1:109–11.

    Article  PubMed  CAS  Google Scholar 

  9. Bell NJV, Burget D, Hunt RH, et al. Appropriate acid suppression for the management of gastro-esopageal reflux disease. Digestion. 1992;51:59–67.

    Article  PubMed  Google Scholar 

  10. Parietal cell Pictures from http://withfriendship.com/user/neeha/parietal-cell.php. Accessed 3 Jan 2012. Image: http://withfriendship.com/images/h/38010/Parietal-cell-pic.gif

  11. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;119:9–31.

    Article  Google Scholar 

  12. Silver MT, Murdock RH, Sue SO. Ranitidine 300 mg twice daily and 150 mg four times daily are effective in healing erosive esophagitis. Aliment Pharmacol Ther. 1996;10:373.

    Article  PubMed  CAS  Google Scholar 

  13. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on Omeprazole: a controlled study in normal subjects. Gastroenterology. 1998;115:1335–9.

    Article  PubMed  CAS  Google Scholar 

  14. Mainie I, Tutian R, Castell DO. Addition of a H2 receptor antagonist to PPI improved acid control and decreased nocturnal acid breakthrough. Clin Gastroenterol. 2008;42:676–9.

    Article  CAS  Google Scholar 

  15. Ours T, Fackler WK, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003;98:545–50.

    Article  PubMed  Google Scholar 

  16. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004;16:441–3.

    Article  PubMed  CAS  Google Scholar 

  17. Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA. Three year follow up of patients with gastroesophageal reflux disease. Gut. 1992;33:1016–9.

    Article  PubMed  CAS  Google Scholar 

  18. Lipsy RJ, Fennerty B, Fagan TC. Clinical review of histamine 2 receptor antagonists. Arch Intern Med. 1990;150:745.

    Article  PubMed  CAS  Google Scholar 

  19. Yu EW, Bauer DC. Acid suppression medications and bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251–9.

    Article  PubMed  CAS  Google Scholar 

  20. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–810.

    Article  PubMed  CAS  Google Scholar 

  21. Robinson M, Hom J. Clinical pharmacology of proton pump inhibitors: what the practicing physician need to know. Drugs. 2003;63:2739–54.

    Article  PubMed  CAS  Google Scholar 

  22. Lew EA. Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther. 1999;13:11–6.

    Article  PubMed  CAS  Google Scholar 

  23. Klotz U. Pharmacokinetic considerations in the eradication of H. pylori. Clin Pharmacokinet. 2000;38:243–70.

    Article  PubMed  CAS  Google Scholar 

  24. Shi S, Klotz U. Proton pump inhibitors: an update on their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935–51.

    Article  PubMed  CAS  Google Scholar 

  25. Mossner J, Caca K. Developments in the inhibition of gastric acid secretion. Eur J Clin Invest. 2005;35:469–75.

    Article  PubMed  CAS  Google Scholar 

  26. Havelund T, et al. Omeprazole and Ranitidine in treatment of reflux esophagitis: double blind comparative trial. Br Med J. 1988;296:89.

    Article  CAS  Google Scholar 

  27. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol. 1996;91:1532.

    PubMed  CAS  Google Scholar 

  28. Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg vs. Omeprazole 40 mg in the treatment of reflux esophagitis. Eur J Gastroenterol Hepatol. 1996;8:1101.

    Article  PubMed  CAS  Google Scholar 

  29. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs Omeprazole in patients with symptoms of gastro-esophageal reflux disease. Aliment Pharmacol Ther. 2000;14:861–7.

    Article  PubMed  CAS  Google Scholar 

  30. Yang YX, Lewis JD, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.

    Article  PubMed  CAS  Google Scholar 

  31. Gray SL, Zhao C, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density on postmenopausal women. Arch Intern Med. 2010;170:765–71.

    Article  PubMed  Google Scholar 

  32. Yu EW, Bauewr SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124:519–26.

    Article  PubMed  CAS  Google Scholar 

  33. Targownik LE, Lix LM, Leung S. Chronic proton pump inhibitor use is not associated with and increased risk of osteoporosis. Gastroenterology. 2009;136:1–70.

    Article  Google Scholar 

  34. Targownik LE, Lix L, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319–26.

    Article  PubMed  Google Scholar 

  35. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008;179:306–7.

    Article  PubMed  Google Scholar 

  36. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of clostridium difficile diarrhea among hospital inpatients prescribed PPIs: cohort and case-control studies. CMAJ. 2004;171:33–8.

    Article  PubMed  Google Scholar 

  37. Linsky A, Gupta K, Lawler E, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.

    Article  PubMed  Google Scholar 

  38. Naggie S, Woods CW, et al. A case-control study of community associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med. 2011;124:276.

    Article  PubMed  Google Scholar 

  39. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with PPI after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322–9.

    Article  PubMed  CAS  Google Scholar 

  40. Li XQ, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821–7.

    Article  PubMed  CAS  Google Scholar 

  41. Bhatt DL. COGENT: a prospective randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Presented at the Transcatheter Cardiovascular Therapeutics, San Francisco, CA, 24 Sep 2009.

    Google Scholar 

  42. Aihara H, et al. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with Clopidogrel following coronary stenting. Cath Cardiovasc Interv. October 1, 2012, Vol 80, Issue 4, pp 556–563

    Google Scholar 

  43. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: as systematic review. Drug Saf. 2012;35(2):127–39.

    Article  PubMed  CAS  Google Scholar 

  44. Toussant J, Gossium A, Deruyttere M, et al. Healing and prevention of relapse of reflux esophagitis by cisapride. Gut. 1991;32:1280–5.

    Article  Google Scholar 

  45. Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA agonist baclofen in patients with GERD. Gut. 2002;50:19–24.

    Article  PubMed  CAS  Google Scholar 

  46. Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D. Arbaclofen placarbil in GERD: a randomized double-blind, placebo-controlled study. Am J Gastroenterol. 2011;106:1427–38.

    Article  PubMed  CAS  Google Scholar 

  47. Boeckxstaens GE, et al. Effect of lesogaberan on transient lower esophageal relaxations in male subjects. Aliment Pharmacol Ther. 2010;31:1208–17.

    Article  PubMed  CAS  Google Scholar 

  48. Vigneri S, Davi G, et al. A comparison of five maintenance therapies for reflux esophagitis. New Engl J Med. 1995;333:1106–10.

    Article  PubMed  CAS  Google Scholar 

  49. Van der Velden A, de Wit NJ, Quartero AO, Grobbee DE, Numans ME. Pharmacological dependency in chronic treatment of GERD: a randomized controlled clinical trial. Digestion. 2010;81:43–52.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI, 53792, USA

    Eric Alan Gaumnitz B.S., M.D.

  2. Department of Medicine, University of Wisconsin Hospital, 600 Highland Avenue, Madison, WI, 53792, USA

    Eric Alan Gaumnitz B.S., M.D.

Authors
  1. Eric Alan Gaumnitz B.S., M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Alan Gaumnitz B.S., M.D. .

Editor information

Editors and Affiliations

  1. , Department of Medicine, University of Wisconsin School of Medici, 600 Highland Avenue, Madison, 53792-9988, Wisconsin, USA

    Keith C. Meyer

  2. , Division of Pulmonary and Critical Care, University of Washington School of Medic, Campus Box 356175, Seatt;e, 98195, Washington, USA

    Ganesh Raghu

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gaumnitz, E.A. (2012). Pharmacologic Treatment of GERD. In: Meyer, K., Raghu, G. (eds) Gastroesophageal Reflux and the Lung. Respiratory Medicine, vol 2. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4614-5502-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5502-8_12

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4614-5501-1

  • Online ISBN: 978-1-4614-5502-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation